Inventiva (ADR)
Developing lanifibranor, an oral MASH candidate, through a pivotal global trial.
$4.71
After-hours close0.00 (0.00%)
At close$4.71(−3.98%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Sep 2026 | −$0.20 | — | — |
| Mar 2026 | −$0.23 | −$1.07 | −365.2% |
| Sep 2025 | −$0.41 | −$1.89 | −361.7% |
| May 2025 | −$0.47 | −$2.69 | −472.9% |
| Sep 2024 | −$0.56 | −$1.01 | −81.1% |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | |||
| Mar 2024 | |||
| Sep 2023 | |||
| Mar 2023 | |||
| Sep 2022 | |||
| Mar 2022 | |||
| Sep 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Dec 2019 | |||
| Jun 2019 | |||
| Dec 2018 | |||
| Jun 2018 | |||
| Dec 2017 | |||
| Jun 2017 | |||
| Dec 2016 | |||
| Jun 2016 | |||
| Dec 2015 | |||
| Jun 2015 | |||
| Jan 2015 | |||
| Jun 2014 | |||
| Jan 2014 | |||
| Jun 2013 | |||
| Jan 2013 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Sep 25, 2026 | −$0.20 | — | — | $4.8M | — | — |
| Mar 30, 2026 | −$0.23 | −$1.07 | −365.2% | $5.2M | $2.3M | −55.3% |
| Sep 25, 2025 | −$0.41 | −$1.89 | −361.7% | $8.7M | $5.2M | −39.8% |
| May 23, 2025 | −$0.47 | −$2.69 | −472.9% | $6.4M | $6.7M | +4.6% |
| Sep 25, 2024 | −$0.56 | −$1.01 | −81.1% | — | $2.9M | — |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | ||||||
| Mar 27, 2024 | ||||||
| Sep 28, 2023 | ||||||
| Mar 29, 2023 | ||||||
| Sep 19, 2022 | ||||||
| Mar 3, 2022 | ||||||
| Sep 20, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 16, 2020 | ||||||
| Dec 31, 2019 | ||||||
| Jun 30, 2019 | ||||||
| Dec 31, 2018 | ||||||
| Jun 30, 2018 | ||||||
| Dec 31, 2017 | ||||||
| Jun 30, 2017 | ||||||
| Dec 31, 2016 | ||||||
| Jun 30, 2016 | ||||||
| Dec 31, 2015 | ||||||
| Jun 30, 2015 | ||||||
| Jan 31, 2015 | ||||||
| Jun 30, 2014 | ||||||
| Jan 31, 2014 | ||||||
| Jun 30, 2013 | ||||||
| Jan 31, 2013 | ||||||